Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[31] Thiotepa, busulfan and fludarabine: A conditioning-regimen for adult patients with acute lymphoblastic leukemia
Banet, A.
Bazarbachi, A.
Labopin, M.
Dulery, R.
Malard, F.
Van de Wyngaert, Z.
Bonnin, A.
Radici, V.
Belhocine, R.
Sestili, S.
El-Cheikh, J.
Mohty, M.
Brissot, E.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 110 - 110
[32] Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation
Dulery, Remy
Bastos, Juliana
Paviglianiti, Annalisa
Malard, Florent
Brissot, Eolia
Battipaglia, Giorgia
Mediavilla, Clemence
Giannotti, Federica
Banet, Anne
Van de Wyngaert, Zoe
Ledraa, Tounes
Belhocine, Ramdane
Sestili, Simona
Adaeva, Rosa
Lapusan, Simona
Isnard, Francoise
Legrand, Ollivier
Vekhoff, Anne
Rubio, Marie-Therese
Ruggeri, Annalisa
Mohty, Mohamad
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (07) : 1407 - 1415
[33] Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes
Chhabra, Saurabh
Narra, Ravi K.
Wu, Ruizhe
Szabo, Aniko
George, Gemlyn
Michaelis, Laura C.
D'Souza, Anita
Dhakal, Binod
Drobyski, William R.
Fenske, Timothy S.
Jerkins, James H.
Pasquini, Marcelo C.
Rizzo, R. Douglas
Saber, Wael
Shah, Nirav N.
Shaw, Bronwen E.
Hamadani, Mehdi
Hari, Parameswaran N.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (05) : 893 - 901
[34] The Impact of Age in Allogeneic Stem Cell Transplantation with Thiotepa Busulfan and Fludarabine (TBF) for Myelofibrosis : A Retrospective Analysis
SORA, Federica
Chiusolo, Patrizia
Giammarco, Sabrina
Innocenti, Idanna
Autore, Francesco
Metafuni, Elisabetta
Galli, Eugenio
Limongello, Maria Assunta
Laurenti, Luca
Sica, Simona
Bacigalupo, Andrea
BLOOD, 2021, 138
[35] Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation
Anne Banet
Ali Bazarbachi
Myriam Labopin
Nicolas Stocker
Rémy Duléry
Florent Malard
Zoé Van de Wyngaert
Alexis Genthon
Mara Memoli
Ollivier Legrand
Agnes Bonnin
Tounes Ledraa
Ramdane Belhocine
Simona Sestili
Jean El-Cheikh
Mohamad Mohty
Eolia Brissot
Bone Marrow Transplantation, 2023, 58 : 61 - 67
[36] Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation
Banet, Anne
Bazarbachi, Ali
Labopin, Myriam
Stocker, Nicolas
Dulery, Remy
Malard, Florent
Van de Wyngaert, Zoe
Genthon, Alexis
Memoli, Mara
Legrand, Ollivier
Bonnin, Agnes
Ledraa, Tounes
Belhocine, Ramdane
Sestili, Simona
El-Cheikh, Jean
Mohty, Mohamad
Brissot, Eolia
BONE MARROW TRANSPLANTATION, 2023, 58 (01) : 61 - 67
[37] Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study
Jiang, Jieling
Li, Xiaofan
Wu, Dong
Lu, Quanyi
Miao, Kourong
Wang, Houcai
Li, Xiaoping
Chen, Yingnian
Zhou, Shiyuan
Zhou, Yali
Liao, Guiping
Jiang, Chuanhe
Yuan, Xiaohong
Zhao, Youshan
Chang, Chunkang
Chen, Jie
Zhu, Han
Ma, Ruye
Li, Nainong
Yin, Xiaolin
Wu, Xiaojin
Wang, Sanbin
Wang, Chun
Hu, Jiong
EJHAEM, 2024, 5 (04): : 757 - 767
[38] Final results of a multicentre phase II randomized study comparing fludarabine-busulfan versus fludarabine-thiotepa as reduced intensity preparative regimen for allogeneic transplantation in patients with myelofibrosis
Patriarca, Francesca
Masciulli, Arianna
Bacigalupo, Andrea
Pavoni, Chiara
Finazzi, Maria Chiara
Bosi, Alberto
Russo, Domenico
Narni, Franco
Messina, Giuseppe
Alessandrino, Emilio Paolo
Cascavilla, Nicola
Milone, Giuseppe
Bruno, Benedetto
Mammoliti, Sonia
Bruno, Barbara
Fanin, Renato
Bonifazi, Francesca
Rambaldi, Alessandro
BONE MARROW TRANSPLANTATION, 2018, 53 : 49 - 49
[39] TREOSULFAN, THIOTEPA AND FLUDARABINE CONDITIONING REGIMEN PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE
Cassanello, Giulio
Bagnoli, Filippo
Saporiti, Giorgia
Goldaniga, Maria
Serpenti, Fabio
Cavallaro, Francesca
Barbullushi, Kordelia
Galassi, Giulia
Barcellini, Wilma
Onida, Francesco
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 264 - 265
[40] Long-Term Survival in Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation Using Fludarabine/Melphalan Conditioning Regimen
Ali, Haris
Aldoss, Ibrahim
Yang, Dongyun
Afkhami, Michelle
Al Malki, Monzr M.
Cao, Thai
Forman, Stephen J.
Marcucci, Guido
Mei, Matthew
Nakamura, Mokhtari Ryotaro
O'Donnell, Margaret
Pillai, Raju
Pullarkat, Vinod
Salhotra, Amandeep
Stein, Anthony S.
Snyder, David S.
BLOOD, 2017, 130

← 1 2 3 4 5 →